Navigation Links
Amylin Pharmaceuticals to Present at Deutsche Bank Health Care Conference
Date:5/12/2009

SAN DIEGO, May 12 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will be presenting at the Deutsche Bank Health Care Conference on Tuesday, May 19, 2009 at 11:30 a.m. ET / 8:30 a.m. PT in Boston. Daniel M. Bradbury, president and chief executive officer of Amylin Pharmaceuticals, will provide a corporate overview.

The live presentation and breakout session will be webcast, and a recording will be made available following the event. The webcast and recording will be accessible through Amylin's corporate Web site, located at www.amylin.com. To access the live webcast, please log on to Amylin's site approximately fifteen minutes prior to the presentation to register and download any necessary audio software.

About Amylin Pharmaceuticals

Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California. Further information about Amylin Pharmaceuticals is available at www.amylin.com.


'/>"/>
SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Amylin Co-Founder Announces Plans to Vote for Eastbourne Slate
2. Amylin Pharmaceuticals Announces a New Sales Approach to Better Target the Diabetes Market
3. Amylin Issues Statement in Response to Carl Icahn
4. Icahn Asks Amylin to Allow Discussions With Eastbourne
5. Amylin Pharmaceuticals Provides Shareholders with Update Regarding Recent Developments
6. Amylin Pharmaceuticals to Present at Cowen and Company Annual Health Care Conference
7. Amylin Pharmaceuticals Confirms Receipt of Director Nomination Notices
8. Amylin Pharmaceuticals Appoints Vincent Mihalik Senior Vice President, Sales and Marketing and Chief Commercial Officer
9. Amylin Pharmaceuticals Highlights 2009 Value Creation Opportunities
10. Amylin Pharmaceuticals Announces Strategic Restructuring and Workforce Reduction
11. Amylin Pharmaceuticals to Present at BIOCOM Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... , July 30, 2014  AtheroNova Inc. (OTCBB: ... and development of compounds to safely regress atherosclerotic ... announces that its partner, CardioNova, has accomplished first ... trial with AtheroNova,s lead compound, AHRO-001.  This Phase ... AHRO-001 Phase 1 safety trial completed in February ...
(Date:7/30/2014)... Diego, CA (PRWEB) July 30, 2014 ... announced their weighing boat special – Buy ... 1 free. This promotion will benefit lab technicians looking ... work. Weighing boats are ideal for multiple applications including ... offers a variety of choices including diamond-shaped, hexagonal, square, ...
(Date:7/29/2014)... significant technological challenges in their quest to improve ... the James Webb Space Telescope. , The team, ... at NASA,s Goddard Space Flight Center in Greenbelt, ... that is, those activated by applying an ... current technology,s magnetically activated arrays. This advance makes ...
(Date:7/29/2014)... HOUSTON (July 29, 2014) Tough, ultralight foam ... and shape through a chemical process invented at Rice ... "GO-0.5BN" looks like a nanoscale building, with floors and ... a pair of two-dimensional materials: floors and walls of ... boron nitride platelets. , The researchers say the ...
Breaking Biology Technology:AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 2AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 3AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 4Weighing Boat Promotion Now Available at Pipette.com, Major Pipette Distributor 2Revolutionary microshutter technology hurdles significant challenges 2Revolutionary microshutter technology hurdles significant challenges 3Revolutionary microshutter technology hurdles significant challenges 4Tough foam from tiny sheets 2
... FRANCISCO, Calif., Jan. 4 Cerimon,Pharmaceuticals, Inc. announced ... Counsel, a newly established position, and Vice President ... global life sciences,executive and corporate attorney with broad ... in the US and,Europe. In the business development ...
... efficacy in treatment of multi-drug ... resistant infections -, ... "Company"), a biopharmaceutical company focused on the,development of novel antibiotics for ... patients in two,separate Phase 2 clinical trials. The studies will evaluate ...
... and biotechnology ... expertise, BOSTON, Jan. 3 Observant LLC has ... for research excellence,and a commitment to client service. John ... firm as Vice President. Dr. Hartman,s,research has focused on ...
Cached Biology Technology:Cerimon Pharmaceuticals Names Matthew J. Meyer its General Counsel and Vice President of Business Development and Licensing 2Rib-X Pharmaceuticals Initiates Two Phase 2 Studies for Novel Antibiotic Compound RX-1741 2Rib-X Pharmaceuticals Initiates Two Phase 2 Studies for Novel Antibiotic Compound RX-1741 3Observant LLC Expands Senior Management Team 2
(Date:7/30/2014)... July 30, 2014 NexID Biometrics ... liveness detection solutions for the biometric authentication industry, ... consortium revolutionizing online authentication with standards for strong ... , "The decision to join FIDO Alliance stems ... pervasive in use. We believe the FIDO Alliance ...
(Date:7/30/2014)... Scientists are searching through a massive collection of 20-million-year-old ... years ago, and the effort is yielding fresh insights ... , When the collection is fully curated, a task ... largest unbiased Dominican amber collection in the world, the ... thus far is that of a pygmy locust, a ...
(Date:7/30/2014)... in cancer treatment has been shown to relieve ... for neural transmission between the peripheral and central ... Institute of Radiation Medicine, Chinese Academy of Medical ... into rat dorsal root ganglia (DRG) to provide ... radioactivity (0, 14.8, 29.6 MBq) were implanted separately ...
Breaking Biology News(10 mins):NexID Biometrics Joins the FIDO Alliance 2Decades-old amber collection offers new views of a lost world 2
... 21 February 2011 Elsevier, a world-leading publisher ... services, and TAIR - The Arabidopsis Information Resource, ... elements of scientific research. All articles on Elsevier,s ... genes and use AGI codes (e.g. AT4G32520) will ...
... Researchers at Albert Einstein College of Medicine ... to protect against an increasingly common and particularly deadly form ... tested in an animal model, are reported in a paper ... Pneumococcal pneumonia can occur when the lungs are ...
... heart diseases affect approximately one in 100 patients, making ... number-one cause of pediatric deaths. Now a new ... cardiac muscle damage in a mouse model of the congenital ... treatment for this rare condition, but also demonstrates the importance ...
Cached Biology News:Vaccine made with synthetic gene protects against deadly pneumonia 2Vaccine made with synthetic gene protects against deadly pneumonia 3Study shows rapamycin reverses myocardial defects in mouse model of LEOPARD syndrome 2Study shows rapamycin reverses myocardial defects in mouse model of LEOPARD syndrome 3
...
Experion spin filters are used to filter the gel matrix and gel stain solution prior to use with the Experion automated electrophoresis system. Supplied as 10 spin filters....
...
... to PRKAR2 cAMP is a signaling ... functions. cAMP exerts its effects by activating ... the signal through phosphorylation of different target ... a tetramer composed of two regulatory and ...
Biology Products: